Predicted protein targets (top 20)
| gene | UniProt | supporting neighbours | confidence | |
|---|---|---|---|---|
| ▸ | MAPK14 | Q16539 | 7/20 | 0.38 |
| ▸ | ACHE | P22303 | 2/20 | 0.33 |
| ▸ | CA9 | Q16790 | 2/20 | 0.33 |
| ▸ | SMN1; SMN2 | Q16637 | 1/20 | 0.33 |
| ▸ | AOC3 | Q16853 | 1/20 | 0.33 |
| ▸ | CA12 | O43570 | 1/20 | 0.33 |
| ▸ | CA1 | P00915 | 1/20 | 0.33 |
| ▸ | CA2 | P00918 | 1/20 | 0.33 |
| ▸ | CA4 | P22748 | 1/20 | 0.33 |
| ▸ | CA7 | P43166 | 1/20 | 0.33 |
| ▸ | CA14 | Q9ULX7 | 1/20 | 0.33 |
| ▸ | MAPT | P10636 | 2/20 | 0.32 |
| ▸ | TDP1 | Q9NUW8 | 1/20 | 0.32 |
| ▸ | CYP3A4 | P08684 | 1/20 | 0.32 |
| ▸ | CYP19A1 | P11511 | 1/20 | 0.32 |
| ▸ | NQO2 | P16083 | 1/20 | 0.32 |
| ▸ | PRMT1 | Q99873 | 1/20 | 0.32 |
| ▸ | KDM4E | B2RXH2 | 1/20 | 0.32 |
| ▸ | ALDH1A1 | P00352 | 1/20 | 0.32 |
| ▸ | HPGD | P15428 | 1/20 | 0.32 |
Click a target to see other patent compounds predicted against it — the reverse direction, in place.
Similar compounds — the chemically nearest patent molecules
Nearest neighbours by Morgan-fingerprint cosine across the patent-compound collection, with each neighbour's top predicted target and the predicted targets it shares with this molecule.
| Compound | similarity | top predicted | shared targets | |
|---|---|---|---|---|
| SCHEMBL1003702 | 0.81 | ACHE (0.37) | MAPK14ACHECA9SMN1; SMN2CA12 | |
| SCHEMBL13406179 | 0.75 | CA1 (0.38) | MAPK14ACHECA9CA12CA1 | |
| Acetic Acid SCHEMBL28354889 | 0.72 | MAPT (0.40) | MAPK14CA9SMN1; SMN2CA12CA1 | |
| SCHEMBL28215184 | 0.72 | HMGCR (0.40) | MAPK14CA9SMN1; SMN2MAPTTDP1 | |
| SCHEMBL3179374 | 0.71 | — | — | |
| SCHEMBL2991243 | 0.70 | CA1 (0.33) | ACHECA9CA12CA1CA2 | |
| SCHEMBL31651724 | 0.70 | CA1 (0.33) | ACHECA9CA12CA1CA2 | |
| SCHEMBL5894749 | 0.68 | MAPT (0.35) | ACHECA9CA12CA1CA2 | |
| SCHEMBL27277668 | 0.67 | SMN1; SMN2 (0.41) | SMN1; SMN2MAPTKDM4EALDH1A1HPGD | |
| SCHEMBL30701949 | 0.67 | CA9 (0.50) | ACHECA9SMN1; SMN2AOC3CA12 |
Similarity is cosine over the 2,048-bit Morgan fingerprint (≈ Tanimoto). Identical fingerprints score 1.00.
Patent provenance — the patents this molecule appears in, and who filed them
Claimed or disclosed in 5 patents. claimed = in the patent's claims; disclosed = body only.
| Patent | Title | Assignee | Published | Priority | Filing | Country | Status |
|---|---|---|---|---|---|---|---|
| EP-2552443-B1 | IMPROVED TREATMENT OF RENAL CELL CARCINOMA | ONCORENA AB (SE) | 2021-07-14 | — | — | EP | disclosed |
| US-9005580-B2 | Treatment of renal cell carcinoma | ONCORENA AB (SE) | 2015-04-14 | — | — | US | disclosed |
| US-20130101507-A1 | Treatment of Renal Cell Carcinoma | ONCORENA AB (SE) | 2013-04-25 | — | — | US | disclosed |
| EP-2552443-A1 | IMPROVED TREATMENT OF RENAL CELL CARCINOMA | ONCORENA AB (SE) | 2013-02-06 | — | — | EP | disclosed |
| WO-2011123027-A1 | IMPROVED TREATMENT OF RENAL CELL CARCINOMA | HARALDSSON BOERJE (SE) | 2011-10-06 | — | — | WO | disclosed |
Patent text — is the patent's own abstract consistent with the prediction?
For each of this compound's patents that has machine-readable text (1 of them — usually the abstract, not the full specification), we ask MedCPT which protein the text reads most about, and where the chemistry-predicted target lands among 4885 human targets. A high rank means the patent's own wording is consistent with the prediction — a weak, independent signal, not proof of activity.
| Patent | Title | Text reads most about | Predicted target · text-rank |
|---|---|---|---|
| US-20130101507-A1 | Treatment of Renal Cell Carcinoma | OGFR, OAT, ASGR1 | MAPK14 2191/4885ACHE 4471/4885CA9 1170/4885 |
“Text reads most about” is the patent abstract's nearest protein in MedCPT space (background-debiased). Only ~1.4% of patents have machine-readable text, so most compounds won't have this panel.